Importantly, since SSX2IP has been identified as an acute myeloid leukaemia-associated antigen and a potential immunotherapy target for leukemia, this study has expanded the usage of those SSX2IP related applications to HCC. Here, SSX2IP is linked to hepatocellular carcinoma.